Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4225843 | 0.98 | S1PR1 (0.38) | S1PR1RORCAAK1LMNAADRB2 | |
| Hydrochloric Acid SCHEMBL27777869 | 0.98 | S1PR1 (0.38) | S1PR1RORCAAK1LMNAADRB2 | |
| SCHEMBL17693919 | 0.86 | RORC (0.37) | S1PR1RORCAAK1LMNAL3MBTL1 | |
| SCHEMBL9988166 | 0.83 | HTR2A (0.34) | S1PR1AAK1SCN9A | |
| SCHEMBL4550399 | 0.83 | SCN9A (0.39) | S1PR1CYP2C9SCN5ASCN9A | |
| SCHEMBL18266454 | 0.83 | SCN9A (0.34) | S1PR1AAK1CYP2C9SCN5ASCN9A | |
| SCHEMBL18266358 | 0.82 | SCN9A (0.33) | S1PR1AAK1CYP2C9SCN5ASCN9A | |
| SCHEMBL4550317 | 0.81 | IDH1 (0.43) | AAK1CYP2C9SMN1; SMN2SCN5ASCN9A | |
| SCHEMBL16045149 | 0.81 | IDH1 (0.43) | AAK1CYP2C9SMN1; SMN2SCN5ASCN9A | |
| Hydrochloric Acid SCHEMBL2715279 | 0.81 | SCN9A (0.38) | S1PR1CYP2C9SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | S1PR1 265/4885RORC 366/4885AAK1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.